CSIMarket
 
Cognition Therapeutics inc   (NASDAQ: CGTX)
Other Ticker:  
 
 
Price: $0.6076 $0.02 3.988%
Day's High: $0.6099 Week Perf: -5.05 %
Day's Low: $ 0.57 30 Day Perf: -17.9 %
Volume (M): 324 52 Wk High: $ 2.95
Volume (M$): $ 197 52 Wk Avg: $1.22
Open: $0.57 52 Wk Low: $0.34



 Market Capitalization (Millions $) 25
 Shares Outstanding (Millions) 40
 Employees 27
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Cognition Therapeutics Inc
Cognition Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative disorders, particularly Alzheimer's disease. The company aims to target the underlying mechanisms of cognitive decline and develop small molecule drugs that can restore cognitive function and slow disease progression. Cognition Therapeutics' innovative approach involves disrupting the interaction between a protein called Sigma-2 receptor and amyloid beta, a protein associated with Alzheimer's disease. By inhibiting this interaction, the company hopes to prevent the toxic effects of amyloid beta and potentially improve memory and cognition in affected individuals.


   Company Address: 2500 Westchester Ave. Purchase 10577 NY
   Company Phone Number: 481-2210   Stock Exchange / Ticker: NASDAQ CGTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC   -8.38%    
AMGN        1.22% 
BIIB   -1.74%    
CHRS   -0.88%    
GILD        10.54% 
HALO        0.29% 
• View Complete Report
   



Clinical Study

Illuminating the Path in Dementia Treatment Cognition Therapeutics? Promising Advances with CT1812

Published Sat, Dec 28 2024 4:35 PM UTC

The field of neurodegenerative research is often marked by incremental progress, punctuated by breakthroughs that redefine our understanding and treatment of complex disorders. Cognition Therapeutics, a notable player in the development of innovative therapies for neurodegenerative diseases, has shed new light on the potential of CT1812. Recent announcements from the company...

Clinical Study

A Milestone in Dementia Treatment Cognition Therapeutics Advances with Phase 2 SHIMMER Study Completion

Published Tue, Nov 26 2024 12:31 PM UTC

In an ambitious stride towards combating dementia, Cognition Therapeutics, Inc. has announced the culmination of all participant visits in the eagerly anticipated Phase 2 SHIMMER study, which investigates the efficacy of CT1812 in Dementia with Lewy Bodies (DLB). The medical and scientific community now awaits the release of topline results, due in December 2024, as these fi...

Clinical Study

Biomarkers as Harbingers A Groundbreaking Correlation Between p-tau217 Levels and Cognitive Improvement in Alzheimer...

Published Mon, Nov 25 2024 12:31 PM UTC

Abstract Alzheimer s disease (AD) remains a numbing specter over millions worldwide, with traditional therapeutic approaches often falling short in addressing its insidious cognitive decline. Recent studies by Cognition Therapeutics present promising insights, particularly surrounding CT1812 a novel treatment that appears to yield significant cognitive benefits. Notably, thi...

Clinical Study

Advancing Hope Cognition Therapeutics Champions Lewy Body Dementia Awareness While Pioneering Promising Treatments

Published Tue, Oct 1 2024 11:30 AM UTC

As September marks Lewy Body Dementia Awareness Month, Cognition Therapeutics Inc. is taking significant steps to elevate public understanding of this often-overlooked neurodegenerative disorder, while simultaneously advancing its commitment to the development of effective treatments. As the second most common form of dementia, Lewy Body Dementia (LBD) presents unique challe...

Clinical Study

Cognition Therapeutics Reports Positive EEG Results for CT1812 in Alzheimers Phase 2 Study Amidst Lackluster Market ...

Published Thu, Aug 22 2024 11:32 AM UTC

Promising EEG Findings from Cognition Therapeutics Phase 2 SEQUEL Study for Alzheimer s Disease Treatment Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company focused on developing drugs for neurodegenerative disorders, recently announced the publication of EEG findings from its Phase 2 SEQUEL study regarding its lead candidate, CT1812, f...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com